BRIEF published on 03/04/2024 at 08:05, 2 years 1 month ago Defence Therapeutics Gains Significant US Patent for Cancer-Killing AccuTOX® Technology Cancer Treatment Defence Therapeutics AccuTOX® Technology US Patent Antibody-drug Conjugates
PRESS RELEASE published on 03/04/2024 at 08:00, 2 years 1 month ago DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY Defence Therapeutics Inc. is granted a broad U.S. patent for its innovative cancer-killing AccuTOX technology, potentially providing market exclusivity until late 2042 Defence Therapeutics Inc. Broad U.S. Patent AccuTOX Technology Cancer-killing Market Exclusivity
PRESS RELEASE published on 11/07/2023 at 08:00, 2 years 5 months ago DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY
PRESS RELEASE published on 10/25/2023 at 08:00, 2 years 5 months ago DEFENCE’S ACCUTOX® AND ANTIGEN CROSS-PRESENTATION: DISCOVERY LEADS TOWARDS THE DEVELOPMENT OF A GROUDNBREAKING PLATFORM
PRESS RELEASE published on 10/18/2023 at 08:00, 2 years 5 months ago Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER
PRESS RELEASE published on 10/17/2023 at 08:00, 2 years 5 months ago Defence Therapeutics Inc.: DELIVERY OF ENCAPSULATED ACCUTOXTM-CHITOSAN NANOPARTICLES TRIGGERS COMPLETE TUMOR REGRESSION IN ANIMALS WITH PRE-ESTABSLIHED SOLID LYMPHOMA
PRESS RELEASE published on 10/10/2023 at 08:00, 2 years 6 months ago DEFENCE ANNOUNCES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUM® AS AN ANTI-CANCER MOLECULE IN THE JOURNAL OF CANCER SCIENCE
PRESS RELEASE published on 09/25/2023 at 08:00, 2 years 6 months ago DEFENCE’S ACCUM®-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES
PRESS RELEASE published on 09/12/2023 at 08:00, 2 years 7 months ago DEFENCE’S BROAD AND VERSATILE ACCUM® TECHNOLOGY PLATFORM FOCUS ON CANCER THERAPEUTICS
PRESS RELEASE published on 09/05/2023 at 08:00, 2 years 7 months ago DEFENCE’S INNOVATIVE THERAPEUTICS FEATURED ON VIEWPOINT WITH DENNIS QUAID
Published on 04/16/2026 at 23:32, 2 hours 1 minute ago Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
Published on 04/16/2026 at 21:30, 4 hours 3 minutes ago Organto Foods Expands Financing Facilities with Rabobank
Published on 04/16/2026 at 15:20, 10 hours 13 minutes ago Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 2026
Published on 04/16/2026 at 15:00, 10 hours 33 minutes ago FaZe Esports, a GameSquare Company, Announces Partnership with CORSAIR
Published on 04/16/2026 at 23:40, 1 hour 52 minutes ago Coventry Ranks #1 in 2025 Life Settlement League Table Report
Published on 04/16/2026 at 21:37, 3 hours 55 minutes ago Approval of the Offer Document concerning the voluntary tender offer for shares of NEXT RE SIIQ S.p.A.
Published on 04/16/2026 at 21:00, 4 hours 32 minutes ago Vizrt AI Keyer kills the green screen and creates virtual scenes in any environment
Published on 04/16/2026 at 20:35, 4 hours 57 minutes ago EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 19:17, 6 hours 15 minutes ago EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 18:02, 7 hours 31 minutes ago Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026
Published on 04/16/2026 at 17:54, 7 hours 38 minutes ago Aéroports de Paris S.A - March 2026 traffic figures
